Printer Friendly

ISL REPORTS SECOND QUARTER RESULTS

 SAN DIEGO, Feb. 16 /PRNewswire/ -- Intelligent Surgical Lasers, Inc. (NASDAQ: ISLS), which designs and manufactures advanced laser systems for the treatment of a broad range of ophthalmic disorders, announced today results for the second quarter and six months ended Dec. 31, 1992. For the second quarter ended Dec. 31, 1992, the company reported revenues of $619,186 compared with revenues of $366,950 for the same period in fiscal 1992. The company reported a net loss of $1,604,069, or ($0.31) per share, compared with a net loss of $990,368, or ($.22) per share, for the quarter ended Dec. 31, 1991.
 Revenues for the first six months were $806,562 compared with $719,633 for the same period of fiscal 1992. The company reported a net loss of $2,905,408 or ($0.61) per share for the six months ended Dec. 31, 1992, compared with a net loss of $1,713,172 or ($0.39) per share, for the same period in fiscal year 1992. ISL's significant investments in research and development and infrastructure support were responsible for the net loss, however that also resulted in near term benefits for the company, according to Heinz Gisel, chairman and CEO.
 "During the last six months we continued to invest in research and development, manufacturing, sales, marketing and administration," Gisel said. "Our research and development work made tremendous progress, culminating in the introduction in January of ISL's new Eye Laser systems for refractive surgery. We will begin shipping the system to Europe at the end of this month and plan to file for an Investigational Device Exemption (IDE) with the FDA by the end of the first quarter 1993."
 The Eye Laser is the first non-excimer laser system designed for performing all types of refractive surgeries, as well as other therapeutic surgeries within the eye. The company believes that the accuracy, effectiveness and ease-of-use of the system combine to allow doctors to move these procedures from an expensive operating room environment to a less expensive out-patient environment.
 "Our focus on expanding our sales, marketing and administration support network resulted in the company obtaining orders for ISL laser systems at a number of important hospitals and research clinics in countries around the world, including China, Greece and Belgium," Gisel added. "The addition of the Eye Laser to our product line enables us to market two laser systems in Europe and abroad, providing revenue to fuel the clinical trials currently taking place with the Model 2001, and eventually The Eye Laser in the United States. The use of these laser systems internationally for various ophthalmic surgeries also provides us with valuable clinical data."
 Intelligent Surgical Lasers, Inc. (ISL) is a development stage biomedical company which designs and manufactures innovative, technologically advanced laser systems for the treatment of a broad range of ophthalmic disorders. Many of these disorders are difficult or impossible to treat with current lasers or traditional medical instruments. Founded in 1987, ISL completed a public offering in September 1992.
 INTELLIGENT SURGICAL LASERS, INC.
 (A Development Stage Company)
 Condensed Statements of Operations
 (Unaudited)
 Periods ended Dec. 31 Three months
 1991 1992
 Sales $366,950 $619,186
 Costs and expenses:
 Cost of sales 250,978 319,240
 Research and development 668,492 1,065,266
 Marketing, general and
 administrative 448,942 856,148
 Total expenses 1,368,412 2,240,654
 Loss from operations (1,001,462) (1,621,468)
 Interest income 11,094 17,399
 Net loss (990,368) (1,604,069)
 Net loss per share $(0.22) $(0.31)
 Shares used in computation
 of net loss per share 4,433,165 5,126,395
 Periods ended Dec. 31 Six months 12/24/87
 (inception)
 1991 1992 through 12/31/92
 Sales $719,633 $806,562 $2,919,706
 Costs and
 expenses:
 Cost of sales 480,978 423,599 1,794,651
 Research and
 development 1,251,064 1,852,833 12,712,842
 Marketing, general
 and
 administrative 734,878 1,434,334 5,932,396
 Total expenses 2,466,920 3,710,766 20,439,889
 Loss from
 operations (1,747,287) (2,904,204) (17,520,183)
 Interest income 34,115 21,444 418,735
 Interest expense -- (22,288) (86,230)
 Net loss (1,713,172) (2,905,048) (17,187,678)
 Net loss per share $(0.39) $(0.61)
 Shares used in
 computation of net
 loss per share 4,438,260 4,750,155
 -0- 2/16/93
 /CONTACT: Heinz R. Gisel, chairman and CEO of ISL, Inc., 619-552-6700, or Linda Seaton of Keatinge-Seaton Communications, 619-625-2100, for ISL/
 (ISLS)


CO: Intelligent Surgical Lasers, Inc. ST: California IN: MTC SU: ERN

TM -- NY018 -- 6743 02/16/93 09:16 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 16, 1993
Words:783
Previous Article:MASSMUTUAL REPORTS STRONG FINANCIAL PERFORMANCE FOR 1992
Next Article:LAC MINERALS LTD. ANNOUNCES 1992 EXPLORATION RESULTS
Topics:


Related Articles
ISL INTRODUCES NEW LASER SYSTEM FOR REFRACTIVE SURGERY
ISL REPORTS THIRD QUARTER RESULTS
NEW MANAGEMENT STRUCTURE AT ISL
ROPER INDUSTRIES, INC. ANNOUNCES ACQUISITION OF INTERNATIONAL INDUSTRIAL CONTROLS COMPANY
INSULPRO INDUSTRIES INC. REVENUES INCREASE 39% FOR THE YEAR TO DATE
ISL Unveils Clementine Data Mining Solutions Vision.
CB Bancshares, Inc. Announces Merger of City Bank and International Savings and Loan and Change of Accounting Method.
Faster ISL Light Service Upgraded With Remote Access.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters